A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
Status:
RECRUITING
Trial end date:
2026-03-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the pharmacokinetic profile of BGM1812 in the bloodstream.